JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Publicaciones (117) Publicaciones en las que ha participado algún/a investigador/a
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45
-
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
Clinical and Translational Oncology
-
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma
Clinical Genitourinary Cancer
-
Molecularly Defined Renal Carcinomas
Kidney Cancer, Vol. 8, Núm. 1, pp. 31-44
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126
-
Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply
Actas Urologicas Espanolas
-
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
Oncologist, Vol. 28, Núm. 6, pp. 501-509
-
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
Future Oncology, Vol. 19, Núm. 12, pp. 819-828
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology, Vol. 41, Núm. 18, pp. 3339-3351
-
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
European Urology Open Science
-
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3556-3564
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities
European urology oncology, Vol. 5, Núm. 6, pp. 726-731
-
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
European Urology, Vol. 82, Núm. 3, pp. 283-292
-
Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning
Oncotarget, Vol. 13, pp. 237-256
-
Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
Cancers, Vol. 14, Núm. 2